

Haematologica
HAEMATOL/2017/183418
Version 3

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

Gail J Roboz, Ellen K. Ritchie, Yulia Dault, Linda Lam, Danielle C. Marshall, Nicole M. Cruz, Hsiao-Ting C. Hsu, Duane C. Hassane, Paul J. Christos, Cindy Ippoliti, Joseph M. Scandura, and Monica L. Guzman

Disclosures: Dr. Roboz has consulted for Janssen Pharmaceutica and received compensation. Dr. Christos was partially supported by the following grant: Clinical and Translational Science Center at Weill Cornell Medical College (UL1-TR000457-06). Dr. Scandura's work is funded by the National Cancer Institute, the National Heart Lung Blood Institute, the NIH Common Fund, the New York State Stem Cell Science program, the Empire Clinical Research Investigator Program, the Leukemia & Lymphoma Society, the Taub Foundation, the Cancer Research & Treatment Fund, the Starr Foundation, and the MPN Research Foundation. Dr. Ritchie, Yulia Dault, Linda Lam, Danielle Marshall, Dr. Cruz, Hsiao-Ting C. Hsu, Dr. Hassane, Cindy Ippoliti, and Dr. Guzman declare no potential conflict of interest.

Contributions: GJR, EKR, JMS, and MLG contributed to protocol design, data collection and analysis, and manuscript preparation. YD, LL, DCM, and CI contributed to data collection. PJC contributed to statistical analysis. NMC, DCH, MLG, and HH contributed to translational laboratory studies.